- Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkins lymphomaby inmunoadminBackground Relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL) remains a major therapeutic challenge despite CD19-directed chimeric antigen receptor (CAR) T-cell therapies, with treatment failure often driven by antigen escape and…
- Rethinking the origins and functions of adaptive immunity. Derick Okwan-Duoduby inmunoadminTrends Immunol. 2026 May 16:S1471-4906(26)00101-8. doi: 10.1016/j.it.2026.04.008. Online ahead of print. ABSTRACT The adaptive immune system (AIS) is traditionally viewed as a defensive vertebrate innovation forged by pathogen pressure. Yet many of its core features suggest it is a homeostatic, regulatory circuit, not simply a sophisticated means of antimicrobial warfare. The horizontal transfer of mitochondria–endogenous … Read more
- Dendritic cell homeostasis in the splenic microenvironmentby inmunoadminCurr Opin Immunol. 2026 May 15;101:102788. doi: 10.1016/j.coi.2026.102788. Online ahead of print. ABSTRACT The spleen is a central immune organ that surveys blood-borne pathogens and coordinates systemic immune responses. Within this organ, conventional dendritic cell (cDC) subsets occupy blood-exposed niches that enable efficient antigen capture and rapid initiation of T cell activation. While splenic cDC1s … Read more
- Latin American regional diversity of T-cell responses and cytokine immunoregulation in human Trypanosoma cruzi infection. Cristina Alonso-Vegaby inmunoadminSemin Immunol. 2026 May 15;82:102030. doi: 10.1016/j.smim.2026.102030. Online ahead of print. ABSTRACT Chagas disease, caused by Trypanosoma cruzi, remains one of the most striking examples of how parasite genetic diversity and host immune heterogeneity converge to shape chronic infection outcomes. This review integrates findings from studies across Latin America -Mexico and Central America, the Andean … Read more
- The therapeutic exploitation of IL-1 in cancer: Controlling tumor progression and resistance to targeted therapies. Valerio Gelfoby inmunoadminSemin Immunol. 2026 May 15;82:102031. doi: 10.1016/j.smim.2026.102031. Online ahead of print. ABSTRACT The interleukin-1 (IL-1) superfamily encompasses a group of cytokines with central roles in inflammation and immune regulation. IL-1 is directly implicated in activating survival and proliferative pathways in transformed cells, orchestrating the angiogenic switch, remodeling the extracellular matrix, and driving invasion and metastatic … Read more